BEVESPI Drug Patent Profile
✉ Email this page to a colleague
When do Bevespi patents expire, and when can generic versions of Bevespi launch?
Bevespi is a drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this drug.
The generic ingredient in BEVESPI is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.
DrugPatentWatch® Generic Entry Outlook for Bevespi
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BEVESPI?
- What are the global sales for BEVESPI?
- What is Average Wholesale Price for BEVESPI?
Summary for BEVESPI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for BEVESPI |
| DailyMed Link: | BEVESPI at DailyMed |
US Patents and Regulatory Information for BEVESPI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | 8,324,266 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | 8,815,258 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | 8,703,806 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | 10,716,753 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | 9,415,009 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
